Ocena skuteczności, bezpieczeństwa i tolerancji fingolimodu u chorych z rzutową postacią stwardnienia rozsianego – obserwacja 12-miesięczna. Doniesienie wstępne by Maciejek, Zdzisław et al.
Neurologia i Neurochirurgia Polska 2013; 47, 2 145
Correspondence address: Zdzis³aw Maciejek, Klinika Neurologiczna, 10 Wojskowy Szpital Kliniczny z Poliklinik¹ SPZOZ, ul. Powstañców Warszawy 5,
85-681 Bydgoszcz, e-mail: z.maciejek@wp.pl
Received: 15.12.2012; accepted: 28.03.2013
Abst ract
Background and purpose: Oral fingolimod 0.5 mg daily was
approved in the European Union in 2011 for the treatment
of relapsing multiple sclerosis in the aggressive form and as
a second line treatment in patients with high disease activity
despite interferon beta therapy. The aim of this study was 
the evaluation of efficacy, safety and tolerance of fingolimod
in patients with relapsing-remitting multiple sclerosis (RRMS)
during a 12-month observation period.
Material and methods: The investigated group consisted of
11 patients aged between 23 and 63 years. All patients under-
went immunomodulatory treatment (disease modifying drugs
– DMD) or immunomodulatory treatment in combination
with mitoxantrone (Mx) without a positive effect for 3-5 years.
Patients received oral fingolimod 0.5 mg daily during 12
months. Disability was evaluated with Kurtzke Expanded Dis-
ability Status Scale (EDSS) scale. Safety and tolerability of
fingolimod were evaluated by adverse events monitoring, la -
boratory tests, and ophthalmological and skin assessment. 
Results: Before the initiation of fingolimod treatment all the
patients progressed in disability and in MRI changes includ-
ing five cases with gadolinium-enhancing lesions. During fin-
golimod treatment there was no new relapse in any patient
and no patient stopped the treatment because of any adverse
event. During the 12-month treatment, EDSS improvement
was observed in seven patients, three patients were stable, and
one patient progressed by 0.5 point in the EDSS.
Evaluation of efficacy, safety and tolerability of fingolimod in patients with 
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Wstêp i cel pracy: Fingolimod uzyska³ w 2011 r. w Unii Eu -
ropejskiej rekomendacjê do leczenia wysoce aktywnej posta-
ci rzutowej stwardnienia rozsianego oraz jako lek drugiego
rzutu – postaci rzutowo-remisyjnej stwardnienia rozsianego
(RRMS) u chorych nieodpowiadaj¹cych na leczenie interfe-
ronem beta. Celem pracy jest wstêpna ocena skutecznoœci,
bezpieczeñstwa i tolerancji fingolimodu u chorych na RRMS
w ci¹gu 12-miesiêcznej obserwacji.
Materia³ i metody: W badaniu wziê³o udzia³ 11 osób z RRMS
w wieku od 23 do 63 lat. Wszyscy otrzymywali leczenie immu-
nomodulacyjne b¹dŸ immunomodulacyjne z immunosupre-
syjnym, bez pozytywnej odpowiedzi w ci¹gu 3–5 lat. Chorzy
stosowali fingolimod – 0,5 mg doustnie raz dziennie – przez
12 miesiêcy. W trakcie leczenia oceniano niesprawnoœæ w skali
niewydolnoœci ruchowej Kurtzkego (Expanded Disability Sta-
tus Scale – EDSS), kontrolowano badania krwi, przeprowa-
dzono konsultacje okulistyczne i dermatologiczne.
Wyniki: We wszystkich przypadkach przed leczeniem fin-
golimodem stwierdzono progresjê niesprawnoœci oraz zmian
radiologicznych w obrazach MRI mózgu, w tym w 5 przy-
padkach obecnoœæ ognisk T1-zale¿nych wzmacniaj¹cych siê
po kontraœcie. W trakcie leczenia fingolimodem u ¿adnego
chorego nie obserwowano nowych rzutów i nie przerwano
leczenia z powodu dzia³añ niepo¿¹danych. W 7 przypadkach
stwierdzono poprawê sprawnoœci w skali EDSS, a w 3 przy-
padkach stan neurologiczny nie uleg³ zmianie; w 1 przypad-
ku nast¹pi³o pogorszenie o 0,5 pkt w EDSS.
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Introduction
Multiple sclerosis (MS) is a major diagnostic and
therapeutic problem. The progress that has been made
in this field over the past several years is a consequence
of the introduction of new diagnostic techniques and
new immunomodulatory drugs inhibiting the inflam-
matory process and reducing accompanying neuronal
and axonal damage [1,2]. Physicians currently treating
MS patients must decide which cases would benefit
from immunomodulatory treatment (interferon beta,
glatiramer acetate) and when a switch to second-line
drugs (fingolimod, natalizumab) would be advisable fol-
lowing lack of favourable response to first-line drugs
[2,3]. Based on recent data encompassing 5-year obser-
vation of the effects of immunomodulatory therapy of
MS, only 33% of patients respond positively to therapy.
A change of treatment is advisable in 37% of cases and
introduction of second-line drugs – in 12% of cases [4].
If no positive response to interferon beta or glatiramer
acetate therapy is noted, the treatment of choice is the
escalation of therapy [3]. Second-line drugs include fin-
golimod and natalizumab [1,3,5,6].
In 2010, fingolimod was approved in the United
States for the treatment of the relapsing form of MS
(relapsing-remitting multiple sclerosis – RRMS). In
2011, the drug was approved for use in the European
Union, though only for very active forms of the disease
and as second-line treatment of RRMS in patients who
do not respond positively to interferon beta therapy. 
The drug is available in the 0.5 mg dose, to be taken
orally once daily [7]. On 1 January 2013, fingolimod
was included in Poland’s drug reimbursement scheme
within the framework of the National Health Fund’s
programme of MS therapy as second-line treatment of
RRMS in patients failing first-line treatment (interfe -
rons beta).
Fingolimod promotes retention of lymphocytes
CD4+ in the lymph nodes. The fingolimod-induced
redistribution of lymphocytes is selective in nature:
naive T cells which are highly implicated in the patho-
genesis of MS and immune memory, including over
90% of IL-17-producing T lymphocytes, become
‘trapped’ in the lymph nodes, while effector lympho-
cytes, which play a major role in defence against infec-
tions, enter the circulation [7]. Phase II and III cli nical
trials conducted to date (FREEDOMS and TRANS-
FORMS) in patients treated with fingolimod have
demonstrated a significant reduction in the relapse rate,
an increase in the proportion of relapse-free patients,
a reduction in gadolinium-enhancing lesions and a de -
crease in brain atrophy compared to the control group.
It should be stressed that serious adverse events (herpes
and varicella-zoster infections) occurred only in indi-
viduals receiving a higher dose of the drug. Other
adverse events included mild herpes outbreaks, upper
respiratory or urinary tract infections, bradycardia, atri-
oventricular block, hypertension, increased liver enzyme
activity and reduced lymphocyte count in peripheral
blood which is attributable to the mechanism of action
of fingolimod [7-9].
The TRANSFORMS trial demonstrated a greater
reduction of the relapse rate in the fingolimod-treated
group vs. interferon beta-treated group, along with
a great er proportion of relapse-free patients and greater
reduction of gadolinium-enhancing lesions. The extend-
ed phase of the trial showed a sustained efficacy benefit
of fingolimod therapy. A significant reduction in the
number of new T2- and T1-weighted lesions was found
in the group of patients initially treated with interferon
beta after switching to fingolimod [8]. A very impor-
tant element of both phases of the TRANSFORMS 
trial was the assessment of brain volume, with a signif-
icant reduction in brain atrophy observed in fingolimod-
treated groups as opposed to the interferon beta-treat-
ed group [8]. 
The year 2011 also saw the publication of results of
a fingolimod efficacy trial conducted in groups of pa -
tients suffering from very active RRMS selected from
among participants of the FREEDOMS and TRANS-
FORMS clinical trials [10]. A comparison of groups
treated with fingolimod, placebo or interferon beta 1-a
demonstrated the greatest benefits of treatment among
fingolimod-treated patients.
Conclusions: In our study patients fingolimod was effective,
safe and well tolerated independently of disease activity and
previous treatment.
Key words: fingolimod, multiple sclerosis – relapsing-remit-
ting form (RRMS).
Wnioski: Leczenie fingolimodem by³o efektywne, bezpiecz-
ne i dobrze tolerowane niezale¿nie od aktywnoœci choroby
oraz wczeœniejszego leczenia.
S³owa kluczowe: fingolimod, stwardnienie rozsiane – postaæ
rzutowo-remisyjna (RRMS).
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Summing up, fingolimod treatment was proven to
be effective regardless of the level of activity of the dis-
ease or prior therapy – also when fingolimod was used
in first-line treatment [10].
The aim of the present study was to perform a pre-
liminary assessment of the efficacy, safety and tolerance
of fingolimod as a second-line drug in patients with the
relapsing form of MS over a 12-month observation
period.
Material and methods
The clinical material consisted of 11 patients with
RRMS (8 women and 3 men) aged between 23 and 63
years (mean age: 40.4 ± 13.4). The average age of MS
onset was 28.7 ± 11.6 years. The mean duration of the
disease was 11.4 ± 4.3 years. The diagnosis was made
on the basis of criteria proposed by McDonald 
et al. [11]. Before the commencement of fingolimod
treatment, all the patients received immunomodulatory
therapy (disease modifying drugs – DMD) based on
interferon beta or glatiramer acetate – or combination
treatment, i.e. immunomodulatory therapy followed by
immunosuppressive treatment with mitoxantrone (Mx)
or inversely, for several (3-5) years, often with two or
more drugs, following lack of positive response to the
first or second immunomodulating drug used. Because
of failure of immunomodulatory and/or immunosup-
pressive treatments, an attempt was made to introduce
fingolimod therapy in accordance with drug registration
guidelines in place in the European Union. None of 
the patients had any contraindications to fingolimod treat-
ment. It should also be noted that flingolimod in a sec-
ond-line treatment indication was not reimbursed until
January 2013, which means it was administered at the
patients’ own expense in all the cases under analysis. 
The clinical data of the patients are listed in Table 1. 
As shown in Table 1, the duration of the disease ex -
ceeded 10 years in the majority of cases. Detailed clinical
characteristics of the study group are given in Table 2.
Fingolimod treatment was commenced with the pro-
cedure comprising one-day hospital stay including elec-
trocardiogram (ECG) and Holter monitoring during the
initial six hours after the administration of the first dose
of the drug, and blood pressure and pulse measurements
performed every hour for 6 hours. Laboratory blood tests
were conducted to assess complete blood count, liver
enzymes and the presence of antibodies against the vari-
cella-zoster virus (in patients who had not previously had
chickenpox). Afterwards the patients received one 0.5 mg
tablet of fingolimod daily, orally, for the forthcoming
months. By now, the duration of drug therapy in the study
group has exceeded 12 months. Throughout the treat-
ment process, the patients were evaluated ophthalmolog-
ically and dermatologically, and assessed clinically in the
Kurtzke Expanded Disability Status Scale (EDSS): ini-
tially once per month (for the first six months of treat-
ment) and then every three months. Laboratory parame-
ters were also monitored, focusing on complete blood
count (lymphocyte count), transaminase (AspAT, AlAT)
Initials Age Sex Age of MS onset MS duration EDSS EDSS after DMD
(years) (F/M) (years) (years) at onset or Mx and DMD
B.R. 52 F 42 10 1.5 4.5
J.M. 50 F 30 20 1.0 4.0
Z.Z. 23 M 19 4 1.0 2.0
A.G. 28 M 18 10 2.0 4.5
E.G. 29 F 17 12 2.0 5.0
G.J. 32 F 22 10 3.0 5.5
Z.K. 58 M 44 14 1.0 5.0
B.T.M. 63 F 51 12 3.0 6.0
A.F. 31 F 23 8 2.0 3.5
B.G. 38 F 26 9 2.0 2.0
S.¯. 41 F 24 17 1.0 4.5
Table 1. Background of demographic and clinical features of investigated group
F – female, M – male, MS – multiple sclerosis, EDSS – Expanded Disability Status Scale, Mx – mitoxantrone, DMD – disease modifying drugs 
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activity, creatinine and plasma lipids. Due to the limited
number of patients observation outcomes were present-
ed for each of the patients individually. 
Results
Results of the study are presented in Table 3. 
It should be noted that in 11 cases second-line treat-
ment was introduced in patients when their physical per-
formance deteriorated, either during or after immu -
nomodulatory treatment. Seven out of 11 patients had
a marked disability (EDSS 4.0-6.0). In all the reported
cases there had been a progression in physical disabili-
ty, assessed by EDSS, and in radiological damage, eval-
uated by brain magnetic resonance imaging (MRI),
before the introduction of fingolimod treatment. In five
cases, T1-weighted lesions enhancing after contrast
medium administration had been identified.
Initials Symptoms Number of Number of DMD or DMD MRI after DMD MRI Gd+after
at onset relapses before relapses during and Mx treatment DMD treatment
DMD treatment and after DMD treatment
treatment
B.R. Pyramidal 2 2 Avonex Progression No
syndrome 4 Copaxone of lesions
(paraparesis)
J.M. Sensory signs 2 3 Betaferon Progression No
3 Mitoxantrone of lesions
Z.Z. Optic neuritis, 2 1 Betaferon Progression No
right-sided 3 of lesions
pyramidal 
syndrome
A.G. Pyramidal 2 3 Betaferon Progression No
syndrome 5 Mitoxantrone of lesions
(paraparesis)
E.G. Pyramidal 2 3 Rebif Progression Yes
syndrome 3 Avonex of lesions
(paraparesis) 1 Tysabri
2
G.J. Sensory signs, 2 2 Copaxone Progression Yes
pyramidal 1 Avonex of lesions
syndrome 1 Betaferon
(paraparesis) 0 Mitoxantrone
Z.K. Sensory signs, 2 2 Rebif Progression Yes
pyramidal 1 Mitoxantrone of lesions
and cerebellar 
syndrome
B.T.M. Pyramidal 2 3 Mitoxantrone + Progression No




A.F. Optic neuritis 2 2 Rebif Progression Yes
of lesions
B.G. Pyramidal 2 0 Avonex Progression Yes
and cerebellar 4 of lesions
syndrome
S.¯. Optic neuritis 7 No medication Progression No
of lesions
Table 2. Clinical characteristics of investigated group
DMD – disease modifying drugs, Mx – mitoxantrone, MRI – magnetic resonance imaging, Gd+ – gadolinium-enhancing lesion
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In seven cases, an improvement in physical perfor-
mance assessed by EDSS was seen during the 12-month
observation period. In three cases, the patients’ neuro-
logical condition remained stable, whereas in one case
there was a deterioration by 0.5 point (in the visual sys-
tem). During the minimum of 12 months of fingolimod
treatment there were no new relapses of the disease or
serious adverse events. One patient developed a urinary
infection, while three patients were diagnosed with ele-
vated serum cholesterol levels. Lymphopenia was found
in seven out of 11 patients, however none of the cases
required drug discontinuation. It must also be empha-
sized that the study patients had no cardiac dysrhythmia
or macular oedema. Similarly, no significant increases
in liver enzyme activity were identified. None of the pa -
tients showed a more pronounced susceptibility to her-
pes infections.
Discussion
Ever since fingolimod was approved by the U.S.
Food and Drug Administration in 2010, treatment with
the drug has been prescribed to a total of 52 000 patients
every year. To date, fingolimod has been approved for
MS therapy in 65 countries across the world. To en -
hance the safety profile of the drug taken orally at a dose
of 0.5 mg daily, the following actions are recommend-
ed: monitoring of peripheral blood CBC values for six
months from the start of therapy, monitoring of liver
enzyme activity, bilirubin concentration, ECG testing.
Patients who have not had chickenpox, or who have not
been vaccinated for chickenpox, should undergo sero-
logical tests. If no antibodies are identified, considera-
tion should be given to vaccinating the patient against
the disease (and administering the drug a month after
vaccination). The patient’s pulse and blood pressure
should be monitored prior to and for six hours after the
administration of the first dose of the drug. Vaccination
with attenuated vaccines should be avoided during the
period of treatment. The European Union guidelines
recommend lymphocyte count monitoring and discon-
tinuation of treatment if the lymphocyte count drops
below 0.2 × 109/L. Ophthalmological examination
should be performed within 3-4 months from the initi-
ation of fingolimod treatment and every time the patient
reports any visual disturbances; the guidance applies, in
particular, to diabetics and patients with a history of
uveitis. If there are appropriate indications, spirometry
should be performed. The activity of liver enzymes
should also be monitored at regular intervals (in the EU:
at 1, 3 and 6 months of treatment). Women of repro-
ductive age are advised to use effective contraception
[1,6,12,13].
The own studies reported here involved patients pre-
treated with at least one immunomodulatory drug before
being enrolled in fingolimod treatment. In three cases,
treatment was followed by mitoxantrone therapy. An im -
provement in physical performance evaluated in the
EDSS scale was observed in seven out of 11 patients
over the 12-month observation period. The remaining
Initials Clinical symptoms before treatment EDSS before EDSS after
treatment 12-month treatment
B.R. Pyramidal and cerebellar syndrome (bilateral) 4.5 4.0
J.M. Bilateral pyramidal syndrome, superficial sensation disorders 4.0 4.0
Z.Z. Right-sided pyramidal syndrome, superficial sensation disorders 2.0 2.0
A.G. Pyramidal and cerebellar syndrome (bilateral) 4.5 4.5
E.G. Pyramidal and cerebellar syndrome (bilateral) 6.0 5.0
G.J. Pyramidal and cerebellar syndrome (bilateral) 6.0 5.0
Z.K. Pyramidal and cerebellar syndrome (bilateral) 6.0 5.0
B.T.M. Pyramidal and cerebellar syndrome (bilateral) 6.0 5.5
A.F. Visual disturbances, pyramidal and cerebellar syndrome (bilateral) 3.5 4.0
B.G. Pyramidal and cerebellar syndrome (bilateral) 3.0 2.5
S.¯. Visual disturbances, pyramidal and cerebellar syndrome (bilateral) 4.5 4.0
Table 3. Clinical characteristics of patients treated with fingolimod before and after 12-month treatment
EDSS – Expanded Disability Status Scale
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patients, with the exception of one (deterioration of visu-
al acuity), were neurologically stable. Throughout the
12 months of observation there were no new relapses of
the disease or serious adverse events. Most members of
the patient group under discussion had highly active dis-
ease, and failed to respond to immunomodulatory ther-
apy and, in some cases, to immunosuppressive therapy.
The outcomes of the own studies are consistent with
published results of clinical trials conducted in groups
of patients with highly active RRMS [10,13]. The stud-
ies comprised three groups of patients. The first group
consisted of patients with one or more relapses in the
year preceding the clinical trial. The second group in -
cluded patients with one relapse and at least one gadolin-
ium-enhancing lesion (Gd+) or nine T2-weighted le -
sions identified by MRI. The third group consisted of
previously untreated patients with three or two relapses
during the year preceding the year of clinical trial enrol-
ment and at least one Gd+ lesion verified by MRI. 
The effects of therapy achieved in the group of patients
treated with fingolimod 0.5 mg daily were compared to
patients receiving placebo or interferon beta 1-a intra-
muscularly at a dose of 30 μg per week. The greatest ben-
efits of treatment were demonstrated in the group treat-
ed with fingolimod vs. placebo or interferon beta 1-a.
The 2012 Annual Meeting of the American Acad-
emy of Neurology in New Orleans saw the presentation
of 7-year data from a phase II extension study of fin-
golimod treatment (1.25 mg vs. 5 mg, once daily) in
relapsing MS. The findings included sustained benefi-
cial effect, i.e. reduced activity of the disease, compared
to the group in which treatment was not continued, and
good tolerance of the drug. No new relapses of the dis-
ease were confirmed in 55% and 66% of patients who
completed 7-year fingolimod treatment, while 83% of
patients were free of contrast-enhanced lesions. Adverse
events included nasopharyngitis (40.9%), headaches
(31.3%), herpes (16 cases) and skin malignancies (14 ca -
ses). The overall tolerance of the drug was good. No
atrioventricular conduction disorders were observed dur-
ing the 7-year observation period [14].
The 2012 Meeting of the European Neurological
Society in Prague featured a presentation of results of
the study conducted by Kappos et al. to provide a pre-
liminary assessment of safety and tolerance of fingolimod
0.5 mg taken orally once daily during the first four
months of therapy (FIRST study). The multi-centre
trial involved a total of 2417 RRMS patients including
diabetics, individuals suffering from bronchial asthma
and certain cardiac diseases, aged up to 65 years, with
disability status up to 6.5 points assessed by EDSS [15].
Clinical data were obtained for 94.4% of patients. Ad -
verse events occurred in 75.3% of patients. The most
common were: nasopharyngitis (14.8%), headaches
(11.3%), lymphopenia (9.4%) and fatigue (6.6%). Infec-
tions developed in 34.3% of patients, with herpes virus
infections (chiefly orolabial herpes) accounting for 4.9%
of cases. Serious adverse events were confirmed in 4.1%
of patients. Sixteen patients (0.7%) developed macular
oedema, while 9 patients (0.4%) were diagnosed with
skin cancer (other than melanoma). A total of 16 patients
discontinued treatment due to abnormal liver test results.
The type and incidence of adverse events did not differ
from those identified during the initial six months of
therapy in previous clinical trials [15].
The findings of the preliminary studies, including
low proportion of patients who discontinued treatment,
show that fingolimod is well tolerated across a broad
spectrum of RRMS forms. 
Conclusions
Fingolimod treatment was effective regardless of the
activity of the disease and prior immunomodulatory and
immunosuppressive therapy. It is worth emphasizing
that the study reported above is the first preliminary
observation of fingolimod treatment in patients with the
relapsing form of MS, conducted in line with the cur-
rent criteria regulating the introduction of second-line
drug.
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